Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Minimum Information about… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization

Artikel i vetenskaplig tidskrift
Författare A. Fuchs
M. Gliwinski
N. Grageda
R. Spiering
A. K. Abbas
S. Appel
R. Bacchetta
M. Battaglia
D. Berglund
B. Blazar
J. A. Bluestone
M. Bornhauser
A. ten Brinke
T. M. Brusko
N. Cools
M. C. Cuturi
E. Geissler
N. Giannoukakis
K. Golab
D. A. Hafler
S. M. van Ham
J. Hester
K. Hippen
M. Di Ianni
N. Ilic
J. Isaacs
F. Issa
D. Iwaszkiewicz-Grzes
E. Jaeckel
I. Joosten
D. Klatzmann
H. Koenen
C. van Kooten
Olle Korsgren
K. Kretschmer
M. Levings
N. M. Marek-Trzonkowska
M. Martinez-Llordella
D. Miljkovic
K. H. G. Mills
J. P. Miranda
C. A. Piccirillo
A. L. Putnam
T. Ritter
M. G. Roncarolo
S. Sakaguchi
S. Sanchez-Ramon
B. Sawitzki
L. Sofronic-Milosavljevic
M. Sykes
Q. Z. Tang
M. Vives-Pi
H. Waldmann
P. Witkowski
K. J. Wood
S. Gregori
C. M. U. Hilkens
G. Lombardi
P. Lord
E. M. Martinez-Caceres
P. Trzonkowski
Publicerad i Frontiers in Immunology
Volym 8
ISSN 1664-3224
Publiceringsår 2018
Publicerad vid Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi
Språk en
Länkar doi.org/10.3389/fimmu.2017.01844
Ämnesord minimum information model, T regulatory cells, immunotherapy, good manufacturing practice, cell, chimeric antigen receptor, versus-host-disease, adoptive transfer, in-vitro, transplantation, blood, expansion, allograft, tolerance, therapies, Immunology
Ämneskategorier Mikrobiologi och immunologi

Sammanfattning

Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?